AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Crispr Therapeutics Board Director Simeon George Purchases $51.5 Million in Shares
ByAinvest
Sunday, Jul 20, 2025 1:51 am ET1min read
Crispr Therapeutics (NASDAQ:CRSP) disclosed a $51.5 million stock purchase by board director Simeon George in an SEC filing. The company's stock surged as much as 21% on Friday, marking its biggest intraday gain since February, and is now up around 58.4% year-to-date.
Crispr Therapeutics (NASDAQ:CRSP) experienced a significant stock surge following a major insider purchase. On July 16, 2025, the company's board director, George Simeon, purchased $51.5 million worth of shares [2]. The stock surged by as much as 21% on Friday, marking its biggest intraday gain since February [3]. As a result, the stock is now up around 58.4% year-to-date [2].The purchase was disclosed in an SEC filing, indicating that Simeon bought 989,812 shares at a price of $52.03 each [4]. This substantial investment by an insider has sparked interest among investors, contributing to the stock's recent performance.
Analysts have mixed views on CRISPR Therapeutics' future prospects. While the average target price is projected at $80.84, with high estimates at $268.00 and lows at $32.00, the average brokerage recommendation is a solid 2.2, translating to an "Outperform" rating [3]. GuruFocus offers a more conservative estimate, setting the GF Value at $36.68, implying a potential downside of 41.66% from the current price of $62.875 [3].
Despite the stock's recent gains, CRISPR Therapeutics reported a net loss of $136 million in the first quarter of 2025, with revenues jumping by 71.6% to $865 million [4]. The company is expected to release its second quarter earnings performance in the first week of August 2025.
References:
[1] https://www.sec.gov/Archives/edgar/data/1674416/000095017025096666/xslF345X05/ownership.xml
[2] https://seekingalpha.com/news/4468897-crispr-director-george-buys-515m-of-shares
[3] https://www.gurufocus.com/news/2987913/crsp-surges-after-major-stock-purchase-by-board-director
[4] https://finance.yahoo.com/news/crispr-therapeutics-crsp-soars-18-181654598.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet